Innovative policy of european institutes in solving cancer problems. The General Assembly of OECI, Genoa, Italy, May 21–24 by Chekhun, V.F.
Experimental Oncology ��� �������� ���� ���ne� ���
The General Assembly and Scientific week of 
OECI �Organization of E�ropean Cancer Instit�tes� 
took place in Genoa �Italy� on ����4 of May. The 
membership of OECI comprises 5� E�ropean cancer 
instit�tions� incl�ding R.E. Kavetsky Instit�te of Experi­
mental Pathology� Oncology and Radiobiology of NAS 
of Ukraine as the only representative from Ukraine. 
In the frames of Scientific week several important 
events took place: meeting on translational oncogeno­
mics� workshop on cancer biotherapy� symposi�m 
on nanotechnology application in oncology� seminar 
on accreditation. OECI General Assembly closed the 
Scientific week.
In the opening speech the OECI president Dr. Ulrik 
Rinborg has drawn attention to the modern interna­
tional co�rse of advances of E�ropean oncology inves­
tigations and co�rse of development of translational 
medicine on the basis of biomedical knowledge� which 
is the central problem of Lisbon strategy to transform 
the E�ropean Union economics to the most competi­
tive and dynamic economics in the world.
The idea to join the efforts of E�ropean instit�tes 
stands o�t thro�gh all activities in Genoa. So� the 
project TRANSFOG �Translational and F�nctional 
Oncogenomics�� sponsored by EU� was created to 
join the efforts of scientists and ind�strial gro�ps in 
systematic identification and f�nctional characteriza­
tion of new cancer genes with high diagnostic and 
therape�tic potential in mammary and l�ng t�mors. 
The final aim of the project is to investigate the t�mor 
specific genomic signat�res and to identify potential 
new molec�lar targets of innovative therapy — the 
genes that control the key biological f�nctions and 
play important role in t�mor progression.
D�ring the seminar “The discovery of new worlds in 
medicine: �se of nanotechnology in cancer prevention 
and therapy” the leading E�ropean experts disc�ssed 
and gave recommendations on nanobiology and 
nanomedicine development� which have to red�ce 
the r�nning costs of p�blic health. Dr. Peter Scharff 
�Germany� presented the research res�lts obtained 
in collaboration with IEPOR of NAS of Ukraine and 
Kiev State University. Nowadays� nanotechnologies 
of the first generation� s�ch as liposomes and alb�­
min nanoparticles� are widely �sed in clinics all over 
the world. The second­generation nanoparticles� so 
called nanovectors� are c�rrently �ndergoing clinical 
trials. The third­generation nanoparticles are �nder 
constr�ction and they co�ld be named m�lti­stage 
particles or MSPs� which are intended for passing over 
the m�ltiple biological barriers.
The Scientific week was closed by OECI Gene­
ral Assembly� devoted to the strategic q�estions of 
�nification of National and E�ropean reso�rces to 
overcome fragmentation in scientific research and to 
achieve fast progress in medical ind�stry.
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